{"id":"W2096367061","doi":"10.1016/s1470-2045(14)70440-1","title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":788,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"Novartis Pharmaceuticals Corporation; Celgene; Amgen","keywords":"Panobinostat; Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Placebo; Clinical endpoint; Internal medicine; Oncology; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001808858,0.002980065,0.005549759,0.000599483,0.0006367566,0.001459151,0.00134047,0.002235497,0.008686832],"category_scores_gemma":[0.001662271,0.001152227,0.003090727,0.0007481135,0.00214812,0.001629895,0.0007115466,0.00443294,0.001579411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001152069,"about_ca_system_score_gemma":0.00135202,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001930443,"about_ca_topic_score_gemma":0.0035191,"domain_scores_codex":[0.9993064,0.0003369617,0.00003833584,0.00015302,0.00003933867,0.0001258889],"domain_scores_gemma":[0.9990452,0.0002477147,0.0002082147,0.00007075458,0.00005072937,0.000377413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9931883,0.001340856,0.0001245124,0.000264906,0.0004336179,0.00001366001,0.00002279177,0.0001547938,0.000829439,0.0000432641,0.0002084862,0.003375373],"study_design_scores_gemma":[0.9718627,0.02689808,0.0004735631,0.00001495438,0.0002304879,0.00001178716,0.00001361256,0.0001410891,0.00009320764,0.00008340112,0.0001687603,0.000008304907],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843789,0.006728339,0.0006546141,0.001258135,0.001357564,0.00285176,0.001037189,0.0001572049,0.001576337],"genre_scores_gemma":[0.9816191,0.004670794,0.001535941,0.001520772,0.0008686885,0.003392431,0.001207137,0.00004199996,0.005143092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008686832,"threshold_uncertainty_score":0.02906036,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0441648861685992,"score_gpt":0.3379999064510631,"score_spread":0.2938350202824639,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}